IntelliPharmaCeutics Intl (IPCI) Shares Gap Down to $0.27

Share on StockTwits

IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) gapped down before the market opened on Thursday . The stock had previously closed at $0.32, but opened at $0.27. IntelliPharmaCeutics Intl shares last traded at $0.21, with a volume of 2300105 shares.

Separately, Maxim Group set a $6.00 target price on IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a report on Thursday, December 20th.

An institutional investor recently bought a new position in IntelliPharmaCeutics Intl stock. Geode Capital Management LLC bought a new position in shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 180,877 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.93% of IntelliPharmaCeutics Intl as of its most recent SEC filing. Institutional investors own 11.05% of the company’s stock.

WARNING: “IntelliPharmaCeutics Intl (IPCI) Shares Gap Down to $0.27” was first posted by Highlight Press and is the property of of Highlight Press. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at

IntelliPharmaCeutics Intl Company Profile (NASDAQ:IPCI)

IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.

Featured Article: Calculating net profit and net profit margin ratio

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with's FREE daily email newsletter.